GCT Industry Ecosystem Breakthrough: Solutions Unveiled at CSGCT Park Tour – Shenzhen Station
Amid the booming development of the biopharmaceutical sector, the gene and cell therapy (GCT) field has been highly sought after by numerous investment institutions over the past decade. As the primary GCT industrial hub in southern China, Shenzhen has leveraged its profound technological foundation, robust industrial ecosystem, and vibrant innovation atmosphere to foster a cohort of outstanding enterprises, including BGI Genomics, Wandao Biotechnology, and Hengrui Yuanzheng.
However, several formidable “mountains” stand in the way of this promising sector: quality control standards, global supply chain competition, and the restructuring of the capital services ecosystem. For Shenzhen’s innovation-driven GCT industry cluster, breaking through these bottlenecks is key to seizing the strategic high ground in the industry.
In terms of quality control, the FDA’s new policy in April, which eliminated mandatory animal testing, has also introduced new challenges for clinical trial applications in the gene and cell therapy (GCT) sector. Although Shenzhen has enacted the *Regulations of Shenzhen Special Economic Zone on Promoting the Cell and Gene Industry*, offering solutions primarily aimed at addressing the difficulties in bringing innovative drugs to market, practical implementation still faces significant hurdles.
In terms of the supply chain, key raw materials such as plasmid DNA and viral vectors have long relied on imports. Although Shenzhen has established a complete industrial chain spanning upstream reagents, midstream R&D, and downstream production, building a secure and stable supply chain system remains an imperative challenge for industrial upgrading.
At the capital level, the average R&D cycle in the GCT field spans 8–10 years, with substantial investment required for each individual product. The traditional phased funding model struggles to meet enterprises’ long-term needs. Although Shenzhen is home to prominent institutions such as Sinopharm Capital and Shenzhen Capital Group, transitioning from “financial investment” to “ecosystem enablement” and helping companies bridge the “valley of death” through resource integration remains a key challenge in achieving deep integration between capital and industry.
On Friday, May 30, from 13:30 to 17:00, the “CSGCT Campus Tour – Shenzhen Stop” event will be grandly launched at Shenzhen Guangming · Bay You Yinli (Guangming Biomedical Innovation Center).This event was hosted by the China Society for Gene and Cell Therapy (CSGCT), the Healthcare Innovation Ecosystem Alliance (HIEA), and Bay Gravity (Guangming Biomedical Innovation Center), with Xingcheng Bio and VectorBuilder as co-organizers.
The event will continue the in-depth discussions from the Guangzhou stop, focusing on Shenzhen’s industrial characteristics. It will invite industry pioneers—including supply chain enterprises, GCT client companies, and seasoned investors—to address three core pain points with practical experience:
Quality Improvement Campaign: Exploring How to Achieve End-to-End Control from R&D to Commercialization
Supply Chain Breakthrough: Analyzing Local Opportunities Amid Global Supply Chain Restructuring
Capital Ecosystem Upgrade: Revealing How Investors Help Companies Improve Clinical Translation Efficiency and Commercialization Success Rates Through Full-Cycle Services Such as Strategic Planning, Technology Integration, and Compliance Guidance
Scan the QR code to register and learn more!
[Go Further Without the Rat Race] CSCGT Campus Tour, Shenzhen Stop
Guest
Zhang Xi
Baiji Bio
Co-founder and Chief Scientific Officer
Dr. Zhang Xi, a graduate of the National University of Singapore, is currently the Co-Founder and Chief Scientific Officer of Singapore-based Baiji Biologics.
Leveraging profound expertise, Dr. Zhang Xi has amassed extensive experience in the research and development of immune cell-based oncology drugs and their clinical translation, successfully securing over thirty scientific achievements and invention patents. Dr. Zhang Xi leads the R&D team in relentless exploration and innovation within the field of immune cell therapy, striving to provide optimal treatment solutions for cancer patients.
Liu Xiao
Xingcheng Bio
Vice President of Business and Marketing
Former Head of Marketing, Greater China, Danaher Biotechnology Group; previously held positions including Asia Pacific Marketing Director, Greater China Marketing Director, Consumables Sales Manager, Business Development Manager, and Product Manager at companies such as Cytiva, GE Life Sciences, PerkinElmer, and Thermo Fisher Scientific.
Ph.D. in Strategy from the University of Montpellier, France; EMBA from Nankai University; M.Sc. in Biology from the University of Manchester; postgraduate studies in Finance at the University of Hong Kong; currently pursuing an M.Sc. in Psychology at Arizona State University, USA. Industry Professor at UCMT; Honorary Director of GDA. Senior Engineer in Measurement, Testing, and Instrumentation in China. Thesis advisor for Doctoral programs in Health Management and Business Administration (DBA/Ph.D.) and the MBA program at the University of Montpellier, France; Distinguished Lecturer for workshops at the Business School of the University of Hong Kong and Nankai University; Lecturer for the Advanced Leadership Training Program on Biopharmaceuticals at Peking University Health Science Center; Guest Lecturer at Yihong Business School. Vice Chairman of the MAH Special Committee under the Chinese Pharmaceutical Enterprise Management Association; Chief Researcher at the Life Sciences Enterprise Research Center of E-Drug Manager; Special Researcher at the China Biomedical Infrastructure Alliance. Planner and Host of the “ChatCGT” column.
Zhang Yang
CITIC Securities
Director, Healthcare & Medical Industry Group
B.S. in Pharmacy from Peking University, Ph.D. in Chemistry from the Institute of Chemistry, Chinese Academy of Sciences, and M.Fin. from the University of International Business and Economics. Candidate for Think Tank Expert at CITIC Group & Healthcare Industry Expert at the Suzhou Branch; Director of the Healthcare Industry Group, Investment Banking Committee, CITIC Securities; licensed to practice in China, Hong Kong, and the United States. Received two “New Fortune” Best Analyst awards in 2021 and a “New Fortune” nomination in a specific category in 2022.
Dr. Zhang Yang joined CITIC Securities in 2014. He completed the RMB 1.18 billion financing for Shanghai Allist Pharmaceutical and the USD 110 million financing for OrbusNeich; handled the IPO of Chengda Biotech, the first company spun off from a Chinese listed enterprise to list on the STAR Market (the first approved “A-share to A-share” spin-off); executed STAR Market IPOs for Yuekang Pharmaceutical, Yuandong Biology, Trophic Biological, Haichuang Pharma, Jinjiang Electronics, Aerospace Taixin, and Yili Pharma; managed the Beijing Stock Exchange IPO for Kangleshishi; handled HKEX IPOs for Chengda Biotech, Hope Medicine, CARsgen Therapeutics, Imeik, Bio-Thera Solutions, and Junshintai Pharma; oversaw the NASDAQ IPO for Keyu Biologics; served as joint lead underwriter for Frontier Biotechnologies and 3SBio; executed refinancing deals for CapBio (the first case under the registration-based system) and Tofflon Science & Technology; advised on China Resources Pharmaceutical’s acquisition of Boya Biotherapeutics, and financing transactions for China Resources Bio-pharmaceutical and Lixin Pharmaceutical. He also provided financial advisory services for CARsgen Therapeutics, Xingfu Chemical, Chengyi Pharmaceutical, CytoTherapy, and Shenda Endoscopy. The cumulative amount of financing facilitated exceeds RMB 23.2 billion.
Inventor of the ZCBI (Zhongguancun Life Science Park CITIC Securities Bioeconomy IPO Index).
Fu Chao
Yanghe Investment
Assistant to the General Manager, Vice President of Investment
Mr. Fu Chao, Assistant to the General Manager and Vice President of Investment at Yanghe Investment. He holds a Master’s degree in Biology from Tsinghua University, dual Bachelor’s degrees in Biotechnology and Finance from Wuhan University, and is a Certified Public Accountant (CPA). With over ten years of investment experience in the biopharmaceutical sector, his portfolio includes Jet Biofil, Kanglu Biotechnology, Mingkang Medical, Genepioneer Biotechnologies, Linkcare Medical, Nuore Medical, Respri, Junyuan Biotechnology, Dayuan Chenguang, Dingbang Biotechnology, Huateng Biotechnology, and Aidigene.
More speakers to be confirmed!
Agenda
Partnership Contact
Event Collaboration:Ms. Chen - 18800157211 (WeChat ID same as phone number)
Event Registration:Mr. Yang - 15360825131 (WeChat ID same as phone number)
Scan the QR code to register and learn more!
On May 29–30, we will also host events at the same venue (Shenzhen Guangming · Bay You Yinli).[The Third Session of 2025 China Biotech Enterprises' Overseas Financing Training]！
From practical cross-border fundraising, NewCo model explanation, laws and regulations and intellectual property rights, pipeline BD financing experience, optimizing pipeline design and other dimensions, we will effectively help solve enterprise-specific problems and accelerate the financing process. We sincerely invite founders, CEOs, CFOs, heads of financing, and senior executives in strategic departments of Chinese Biotech companies that are planning or currently pursuing overseas financing; investors and legal advisors who are interested in overseas financing for Biotech companies to attend!
Click to navigate